Microbiological study of the influence of an immunomodulator on the antimicrobial activity of the decametoxin antiseptic agent with their combined application

Abstract

Annotation. The article presents the results of a microbiological study of the immunomodulator “Blastomunyl” on the antimicrobial activity of the antiseptic decamethoxine in combined use. A microbiological study of the antimicrobial activity of decamethoxine in the presence of different contents of blastomunil was carried out by the macromethod of serial dilutions: sample 1 – contained 0.6 mg of blastomunil in 4 ml of decamethoxine solution, sample 2 – contained 0.6 mg of blastomunil in 8 ml of decamethoxine solution, sample 3 – 0, 6 mg of blastomunil in 10 ml of decamethoxine solution. The antimicrobial activity of the studied samples was studied against reference strains S. aureus ATCC 25923, S. aureus ATCC 29213, E. coli ATCC 25922, E. coli ATCC 35213, K. pneumonie ATCC 700603, P. aeruginosa ATCC 27853, as well as against clinical strains conditionally -pathogenic microorganisms of the Museum of Live Cultures, Bacteriological Laboratory, Department of Microbiology, National Pirogov Memorial Medical University, Vinnytsya, which were isolated from patients with wound purulent-inflammatory diseases (S. aureus (n=17), E. coli (n=17), P. aureginosa (n=17), K. pneumoniae (n= 17), A. baumannii (n=17)). A comparative assessment of the sensitivity of microorganisms to the studied drug samples was carried out according to MBsC and MBcS (in μg/ml of decamethoxine) in comparison with the corresponding indicators of sensitivity to the control solution of 0.02% decamethoxine (decasan). The integrated system STATISTICA® 5.5 (Stat Soft® Snc, USA), license number АХХР910A374605FA, was used to perform statistical calculations. The significance of the difference was determined using the Student's t-test and the Mann-Whitney U-test. As a result of the study, it was established that the combination of blastomunil solution in the amount of 0.3 mg/ml with 0.02% solution of decamethoxine has a certain antagonistic effect, which is accompanied by a significant decrease in the bacteriostatic (p<0.01) and bactericidal (p<0.001) properties of decamethoxine regarding Staphylococcus aureus. At the same time, when creating a composite agent with complex therapeutic properties, it is optimal to use 0.15 mg/ml blastomunyl and 0.02% decamethoxine solution, which provides effective anti-staphylococcal antimicrobial action and additional biologically active therapeutic properties.